WHCM
VYGR icon

Wolf Hill Capital Management’s Voyager Therapeutics VYGR Stock Holding History

Wolf Hill Capital Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-163,200
Closed -$4.16M – 32
2021
Q1 		$4.16M Buy
+163,200
New +$1.11M 1.7% 21

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wolf Hill Capital Management's VYGR Position: Q2 2021 in Review

Wolf Hill Capital Management sold out of Voyager Therapeutics (VYGR) in Q2 2021, closing a stake of 163,200 shares — an estimated $4.16M sold.

Wolf Hill Capital Management first reported a position in VYGR in Q1 2021 and held it in 1 quarter. The position peaked at $4.16M in Q1 2021. 78 funds tracked by Wall St. Rank hold VYGR as of Q2 2021.

  • Wolf Hill Capital Management reported no remaining Voyager Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Wolf Hill Capital Management sold 163,200 Voyager Therapeutics shares in Q2 2021, an estimated $4.16M.
  • Wolf Hill Capital Management first reported a position in Voyager Therapeutics in Q1 2021 and held it in 1 quarter.
  • Wolf Hill Capital Management's Voyager Therapeutics position peaked at $4.16M in Q1 2021.
  • 78 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2021.

Based on Wolf Hill Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.